Hsbc Holdings PLC Buys 27,739 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Hsbc Holdings PLC increased its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 91.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 57,929 shares of the biopharmaceutical company’s stock after acquiring an additional 27,739 shares during the quarter. Hsbc Holdings PLC’s holdings in Catalyst Pharmaceuticals were worth $1,362,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of CPRX. Deerfield Management Company L.P. increased its position in Catalyst Pharmaceuticals by 72.8% in the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after purchasing an additional 2,095,291 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Catalyst Pharmaceuticals by 200.6% during the 4th quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock valued at $40,124,000 after buying an additional 1,147,565 shares in the last quarter. Morgan Stanley raised its position in shares of Catalyst Pharmaceuticals by 59.1% during the 4th quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock valued at $68,466,000 after buying an additional 1,089,775 shares in the last quarter. American Century Companies Inc. raised its position in shares of Catalyst Pharmaceuticals by 43.8% during the 3rd quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock valued at $49,805,000 after buying an additional 770,198 shares in the last quarter. Finally, Fundsmith LLP lifted its holdings in shares of Catalyst Pharmaceuticals by 24.2% in the 3rd quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after acquiring an additional 654,721 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Up 0.0%

Shares of NASDAQ:CPRX opened at $31.44 on Thursday. The business’s 50 day moving average is $30.71 and its 200 day moving average is $26.41. The stock has a market cap of $3.85 billion, a P/E ratio of 18.07, a price-to-earnings-growth ratio of 0.95 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.05 and a 52-week high of $32.56.

Wall Street Analysts Forecast Growth

CPRX has been the topic of several analyst reports. Zacks Research cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Wall Street Zen lowered Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings upgraded Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. Stephens set a $32.00 target price on Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Finally, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $32.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).